Cel-Sci: Fabulous Story Stock Works To Pass Muster With FDA
Summary
- The company's focus is on its cancer pretreatment therapy, Multikine, which aims to boost the immune response before standard cancer treatments.
- After its long years in development, CVM is anxious for quick regulatory approval.
- CEL-SCI's future is highly risky due to the challenges it has faced in the development of Multikine and its financial struggles.
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.